Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American ...
Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...
The City of Greensboro, North Carolina, which provides public safety, emergency, and health services to over 300,000 residents and spends millions annually on insulin medications, filed a lawsuit last ...